BioNTech to acquire CureVac in $1.25B all-stock mRNA deal

breakingthenews.net/Article/BioNTech-to-acquire-CureVac-in-dollar1.25B-all-stock-mRNA-deal/64281648

BioNTech announced Thursday it will acquire CureVac through a $1.25 billion all-stock exchange, aiming to bolster its mRNA-based cancer immunotherapy pipeline. The German biopharma giant will offer ap...

This story appeared on breakingthenews.net, 2025-06-12 14:22:00.
The Entire Business World on a Single Page. Free to Use →